Azienda USL Toscana Centro

Via Suor Niccolina Infermiera 20/22, Prato, 59100, Italy

Neoplasms Research at Azienda USL Toscana Centro

At Azienda USL Toscana Centro in Prato, the clinical trial program is focused on neoplasms, with studies exploring new ways to treat several difficult-to-manage cancers and rare tumors. The research includes work on improving treatment effectiveness, delaying disease progression, and testing promising therapies for both early-stage and advanced disease.

Endometrial cancer research is evaluating a new maintenance approach for advanced or recurrent disease to better control cancer growth.
Studies in colorectal cancer are assessing short-course preoperative targeted treatments for molecularly selected resectable tumors.
Trials in ovarian, fallopian tube, and primary peritoneal cancers are testing maintenance strategies for platinum-sensitive disease.
Breast cancer research covers both ER-positive/HER2-negative early breast cancer and HER2-low or HER2 IHC 0 metastatic breast cancer, with studies aimed at improving anti-tumor activity and treatment outcomes.
A rare tumor study is focused on tenosynovial giant cell tumor, evaluating whether a new therapy can reduce tumor activity.

Overall, the site’s oncology team is investigating therapies designed to improve response rates, extend progression-free survival, and support more effective care across a range of solid tumors.

#1 Clinical Trials Search in Europe

Azienda USL Toscana Centro

Neoplasms Research at Azienda USL Toscana Centro

Rinatabart Sesutecan plus Bevacizumab vs standard care as maintenance for recurrent platinum‑sensitive ovarian cancer after second‑line chemotherapy

Study of LY3484356 (imlunestrant) with Tamoxifen Citrate and Goserelin Acetate in Premenopausal Women with ER‑Positive, HER2‑Negative Early Breast Cancer

Phase 3 Study of Enpatoran in Patients with Active Cutaneous Lupus Erythematosus (with or without Systemic Disease)

Phase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients

A study comparing Rinatabart Sesutecan to other treatments in patients with endometrial cancer who have previously received platinum-based chemotherapy and PD-L1 therapy

Study comparing datopotamab deruxtecan with or without durvalumab to chemotherapy with pembrolizumab for patients with triple-negative breast cancer

A Study Comparing RLY-2608 and Fulvestrant with Capivasertib and Fulvestrant for Patients with PIK3CA-Mutant Hormone Receptor Positive, HER2-Negative Advanced Breast Cancer

A Study of LAD191 Compared to Placebo and Adalimumab in Adults with Moderate-to-Severe Hidradenitis Suppurativa

Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

Study of cemiplimab treatment after surgery in patients with stage II-IIIA non-small cell lung cancer who have not received chemotherapy and have PD-L1 expression of 1% or higher

Azienda USL Toscana Centro

Neoplasms Research at Azienda USL Toscana Centro

We use cookies